Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery

Expert Opinion on Drug Delivery

Volumn 8, Issue 6, 2011, Pages 721-734

  Agüeros, Maite ^a   Espuelas, Socorro ^a   Esparza, Irene ^a   Calleja, Patricia ^a   Peñuelas, Ivan ^b   Ponchel, Gilles ^c   Irache, Juan M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

bioadhesion; bioavailability; cyclodextrin; nanoparticles; oral delivery; paclitaxel

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ATOVAQUONE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; CAMPTOTHECIN; CYCLODEXTRIN; CYCLOSPORIN A; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DEXAMETHASONE; DOXORUBICIN; GANTREZ COPOLYMER; GLUTATHIONE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; METHYL BETA CYCLODEXTRIN; NANOCARRIER; PACLITAXEL; POLYANHYDRIDE; PRASTERONE; RETINOIC ACID; RETINOL; SAQUINAVIR; VERAPAMIL;

ADHESION; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HYDROPHILICITY; ISOTOPE LABELING; LIPOPHILICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR INTERACTION; MOLECULAR STABILITY; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG CARRIERS; HUMANS; NANOPARTICLES; P-GLYCOPROTEIN; PACLITAXEL; POLYANHYDRIDES; SOLUBILITY; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 79956215352     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.572069     Document Type: Review

References (95)

1. Washington C, Washington CG, Wilson CG.Physiological Pharmaceutics. Barriers to Drug Absorption.Taylor and Francis, London; 2001
2. Dahan A, Miller JM, Amidon GL.Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.AAPS J 2009;11:740-6
3. Daugherty AL, Mrsny RJ.Transcellular uptake mechanisms of the intestinal epithelial barrier.Part one.Pharm Sci Technol Today 1999;8:144-51 (Pubitemid 29195747)
4. Daugherty AL, Mrsny RJ.Regulation of the intestinal epithelial paracellular barrier.Pharm Sci Technol Today 1999;2:281-87 (Pubitemid 29331976)
5. Corr SC, Gahan CC, Hill C.M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis.FEMS Immunol Med Microbiol 2008;52:2-12
6. Thummel KE.Gut instincts: CYP3A4 and intestinal drug metabolism.J Clin Invest 2007;117:3173-6 (Pubitemid 350096972)
7. Wacher VJ, Salphati L, Benet LZ.Active secretion and enterocytic drug metabolism barriers to drug absorption.Adv Drug Deliv Rev 2001;46:89-102
8. Bansal T, Akhtar N, Jaggi M, et al.Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation.Drug Discov Today 2009;14:1067-74
9. Stella VJ, Nti-Addae KW.Prodrug strategies to overcome poor water solubility.Adv Drug Deliv Rev 2007;59:677-94 (Pubitemid 47285410)
10. Cai Z, Wang Y, Zhu LJ, Liu ZQ.Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs.Curr Drug Metab 2010;11:197-207
11. Ponchel G, Irache J.Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract.Adv Drug Deliv Rev 1998;34:191-219 (Pubitemid 28535112)
12. Arun R, Ashok Kumar CK, Sravanthi VVNSS.Cyclodextrins as drug carrier molecule: a review.Scientia Pharm 2008;76:567-98
13. Endo T, Nagase H, Ueda H, et al.Isolation, purification and characterization of cyclomaltooctadecaose (nu-cyclodextrin), cyclomaltononadecaose (xi-cyclodextrin), cyclomaltoeicosaose (o-cyclodextrin) and cyclomaltoheneicosaose (pi-cyclodextrin).Chem Pharm Bull 1998;46:1840-43
14. Miyazawa I, Ueda H, Nagase H, et al.Physicochemical properties and inclusion complex-formation of delta-cyclodextrin.Eur J Pharm Sci 1995;3:153-62
15. McCormack B, Gregoriadis G.Drugs-in-cyclodextrins-in-liposomes: a novel concept in drug delivery.Int J Pharm 1994;112:249-58 (Pubitemid 24319842)
16. McCormack B, Gregoriadis G.Entrapment of cyclodextrin-drug complexes into liposomes: potential advantages in drug delivery.J Drug Target 1994;2:449-54
17. Silveira AM, Ponchel G, Puisieux F, Duchene D.Combined poly (isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs.Pharm Res 1998;15:1051-55 (Pubitemid 28356922)
18. Cirpanli Y, Bilensoy E, Lale Dogan A, Calis S.Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery.Eur J Pharm Biopharm 2009;73:82-9
19. Agueros M, Zabaleta V, Espuelas S, et al.Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly (anhydride) nanoparticles.J Control Release 2010;145:2-8
20. Pecchio M.Development and characterization of cyclosporine A-loaded Gantrez AN 119 nanoparticles for oral delivery.In vivo behaviour.Ph.D.Thesis University of Navarra, Pamplona, Spain; 2010
21. Calvo J.Nanoparticles as vehicles for the oral delivery of antimalarial drugs.Ph.D.Thesis University of Navarra, Pamplona, Spain; 2010
22. Martin del Valle EM.Cyclodextrins and their uses: a revies.Process Biochem 2004;39:1033-46
23. Terada Y, Yanase M, Takata H, et al.Cyclodextrins are not the major cyclic alpha-1,4-glucans produced by the initial action of cyclodextrin glucanotransferase on amylose.J Biol Chem 1997;272:15729-33 (Pubitemid 27265546)
24. Takaha T, Yanase M, Takata H, et al.Potato D-enzyme catalyzes the cyclization of amylose to produce cycloamylose, a novel cyclic glucan.J Biol Chem 1996;271:2902-08 (Pubitemid 26055589)
25. Astray G, Gonzalez-Barreiro C, Mejuto JC, et al.A review on the use of cyclodextrins in foods.Food Hydrocol 2009;23:1631-40
26. Loftsson T, Brewster ME, Masson M.Role of cyclodextrins in improving oral drug delivery.Am J Drug Del 2004;2:1-15
27. Shimada K, Kawano K, Ishii J, Nakamura T.Structure of inclusion complexes of cyclodextrins with triglyceride at vegetable oil-water interface.J Food Sci 1992;57:655-56
28. Szejkli J.Past, present, and future of cyclodextrin research.Pure Appl Chem 2004;76:1825-45
29. Singh M, Sharma R, Banerjee UC.Biotechnological applications of cyclodextrins.Biotechnol Adv 2002;20:341-59 (Pubitemid 35348280)
30. Uekama K, Hirayama F, Irie T.Cyclodextrin drug carrier systems.Chem Rev 1998;98:2045-76 (Pubitemid 128633447)
31. Loftsson T, Brewster ME.Pharmaceutical applications of cyclodextrins: basic science and product development.J Pharm Pharmacol 2010;62:1607-21
32. Prabaharan M, Mano JF.Hydroxypropylchitosan bearing beta-cyclodextrin cavities: synthesis and slow release of its inclusion complex with a model hydrophobic drug.Macromol Biosci 2005;5:965-73 (Pubitemid 41546071)
33. Bellanger N, Perly B.NMR investigations of the conformation of new cyclodextrin-based amphiphilic transporters for hydrophobic drugs - Molecular Lollipops.J Mol Struct 1992;273:215-26
34. Bilensoy E, Atilla HA.Recent advances and future directions in amphiphilic cyclodextrin nanoparticles.Exp Op Drug Del 2009;6:1161-73
35. Liu FY, Kildsig DO, Mitra AK.Complexation of 6-acyl-O-betacyclodextrin derivatives with steroids - Effects of chain-length and substitution degree.Drug Dev Ind Pharm 1992;18:1599-612
36. Roux M, Perly B, Djedaini-Pilard F.Self-assemblies of amphiphilic cyclodextrins.Eur Biophys J 2007;36:861-7 (Pubitemid 350045050)
37. Zhang P, Ling CC, Coleman AW, et al.Formation of amphiphilic cyclodextrins via hydrophobic esterification at the secondary hydroxyl face.Tetrahedron Lett 1991;32:2769-70
38. Duchene D, Ponchel G, Wouessidjewe D.Cyclodextrins in targeting: application to nanoparticles.Adv Drug Del Rev 1999;36:29-40
39. Wenz G.Synthesis and characterization of some lipophilic per(2,6-di-O-alkyl) cyclomalto-oligosaccharides.Carbohyd Res 1991;214:257-65 (Pubitemid 21726102)
40. Wouessidjewe D, Skiba M, Leroy-Lechat F, et al.A new concept in drug delivery based on 'skirt-shaped cyclodextrin aggregates' - Present state and future prospects.STP Pharma Sci 1996;6:21-8
41. Fenyvesi F, Fenyvesi E, Szente L, et al.P-glycoprotein inhibition by membrane cholesterol modulation.Eur J Pharm Sci 2008;34:236-42
42. Yunomae K, Arima H, Hirayama F, Uekama K.Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells.Febs Lett 2003;536:225-31 (Pubitemid 36206436)
43. Bardelmeijer HA, van Tellingen O, Schellens JHM, Beijnen JH.The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.Invest New Drug 2000;18:231-41 (Pubitemid 30599143)
44. Schellens JHM, Malingre MM, Kruijtzer CMF, et al.Modulation of oral bioavailability of anticancer drugs: from mouse to man.Eur J Pharm Sci 2000;12:103-10
45. Garrigues A, Escargueil AE, Orlowski S.The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane.Proc Natl Acad Sci USA 2002;99:10347-52
46. Carrier RL, Miller LA, Ahmed M.The utility of cyclodextrins for enhancing oral bioavailability.J Control Release 2007;123:78-99 (Pubitemid 47566400)
47. Arima H, Yunomae K, Hirayama F, Uekama K.Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.J Pharmacol Exp Ther 2001;297:547-55 (Pubitemid 32377984)
48. van Waterschoot RAB, Rooswinkel RW, Wagenaar E, et al.Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver.Faseb J 2009;23(1):224-31
49. Guengerich FP.Cytochrome P-450 3A4: regulation and role in drug metabolism.Annu Rev Pharmacol Toxicol 1999;39:1-17 (Pubitemid 29222549)
50. Lin JH, Lu AYH.Inhibition and induction of cytochrome P450 and the clinical implications.Clin Pharmacokinet 1998;35:361-90 (Pubitemid 28520008)
51. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al.Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.J Clin Invest 2007;117:3583-92 (Pubitemid 350097013)
52. Ishikawa M, Yoshii H, Furuta T.Interaction of modified cyclodextrins with cytochrome P-450.Biosci Biotech Biochem 2005;69:246-8 (Pubitemid 40383513)
53. McCormack B, Gregoriadis G.Drugs-in-cyclodextrins-in-liposomes: an approach to controlling the fate of water insoluble drugs in vivo.Int J Pharm 1998;162:59-69 (Pubitemid 28166091)
54. Duchene D, Ponchel G, Wouessidjewe D.Cyclodextrins and carrier systems.J Control Release 1999;62:263-8 (Pubitemid 29486506)
55. Becirevic-Lacan M, Salko N.Hydrocortisone/cyclodextrin complex.Complexation methods and complex incorporation in liposomes.STP Pharma Sci 1997;7:343-47
56. Loukas YL, Jayasekera P, Gregoriadis G.Characterization and photoprotection studies of a model gamma-cyclodextrin-included photolabile drug entrapped in liposomes incorporating light absorbers.J Phys Chem 1995;99:11035-40
57. Loftsson T, Masson M.Cyclodextrins in topical drug formulations: theory and practice.Int J Pharm 2001;225:15-30 (Pubitemid 32728196)
58. Fatouros DG, Hatzidimitriou K, Antimisiaris SG.Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release.Eur J Pharm Sci 2001;13:287-96 (Pubitemid 32522581)
59. Lira MCB, Ferraz MS, Silva DGVCd, et al.Inclusion complex of usnic acid with beta-cyclodextrin: characterization and nanoencapsulation into liposomes.Incl Phenom Macrocycl Chem 2009;64:215-24
60. Maestrelli F, Gonzalez-Rodriguez ML, Rabasco AM, Mura P.Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery.Int J Pharm 2005;298:55-67 (Pubitemid 40834315)
61. Gillet A, Grammenos A, Compere P, et al.Development of a new topical system: drug-in-cyclodextrin-indeformable liposome.Int J Pharm 2009;380:174-80
62. Maestrelli F, Gonzalez-Rodriguez ML, Rabasco AM, et al.New 'drug-in cyclodextrin-in deformable liposomes' formulations to improve the therapeutic efficacy of local anaesthetics.Int J Pharm 2010;395:222-31
63. Boudad H, Legrand P, Lebas G, et al.Combined hydroxypropyl-beta- cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir.Int J Pharm 2001;218:113-24 (Pubitemid 32406162)
64. Mooguee M, Omidi Y, Davaran S.Synthesis and in vitro release of adriamycin from star-shaped poly(lactide-co-glycolide) nano- and microparticles.J Pharm Sci 2010;99:3389-97
65. Wang T, Zhang C, Liang XJ, et al.Hydroxypropyl-beta-cyclodextrin copolymers and their nanoparticles as doxorubicin delivery system.J Pharm Sci 2010;100:1067-79
66. Jerry N, Anitha Y, Sharma CP, Sony P.In vivo absorption studies of insulin from an oral delivery system.Drug Deliv 2001;8:19-23 (Pubitemid 32179159)
67. Irie T, Uekama K.Cyclodextrins in peptide and protein delivery.Adv Drug Deliv Rev 1999;36:101-23 (Pubitemid 29074479)
68. Sajeesh S, Sharma CP.Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery.Int J Pharm 2006;325:147-54 (Pubitemid 44573692)
69. Zhang N, Li J, Jiang W, et al.Effective protection and controlled release of insulin by cationic beta-cyclodextrin polymers from alginate/chitosan nanoparticles.Int J Pharm 2010;393:212-18
70. Trapani A, Garcia-Fuentes M, Alonso MJ.Novel drug nanocarriers combining hydrophilic cyclodextrins and chitosan.Nanotechnology 2008;19:185101
71. Trapani A, Lopedota A, Franco M, et al.A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides.Eur J Pharm Biopharm 2010;75:26-32
72. Arbos P, Wirth M, Arangoa MA, et al.Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates.J Control Release 2002;83:321-30 (Pubitemid 35223255)
73. Rowe RC, Sheskey PJ, Quinn ME.Handbook of Pharmaceutical Excipients.6th edition.Pharmaceutical Press; North Yorkshire, UK; 2009
74. Arbos P, Campanero MA, Arangoa MA, et al.Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties.J Control Release 2003;89:19-30 (Pubitemid 36412111)
75. Ojer P, Salman H, Martins RDC, et al.Spray-drying of poly(anhydride) nanoparticles for drug/antigen delivery.J Drug Del Sci Technol 2010;20:353-59
76. Agueros M, Areses P, Campanero MA, et al.Bioadhesive properties and biodistribution of cyclodextrin-poly (anhydride) nanoparticles.Eur J Pharm Sci 2009;37:231-40
77. Arangoa MA, Campanero MA, Renedo MJ, et al.Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs.Relationships between bioadhesion and pharmacokinetics.Pharm Res 2001;18:1521-7 (Pubitemid 33022406)
78. Arbos P, Arangoa MA, Campanero MA, Irache JM.Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles.Int J Pharm 2002;242:129-36
79. Areses P, Agueros MT, Quincoces G, et al.Molecular imaging techniques to study the biodistribution of orally administered (99m)Tc-labelled naive and ligand-tagged nanoparticles.Mol Imaging Biol 16 Dec 2010 [Epub ahead of print]
80. Agueros M, Ruiz-Gaton L, Vauthier C, et al.Combined hydroxypropyl-beta- cyclodextrin and poly (anhydride) nanoparticles improve the oral permeability of paclitaxel.Eur J Pharm Sci 2009;38:405-13
81. Jain R, Agarwal S, Majumdar S, et al.Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.Int J Pharm 2005;303:8-19 (Pubitemid 41318017)
82. Bravo-Osuna I, Vauthier C, Chacun H, Ponchel G.Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles.Eur J Pharm Biopharm 2008;69:436-44
83. Rowinsky EK, Donehower RC.Paclitaxel (Taxol).N Engl J Med 1995;332:1004-14
84. Kruijtzer CM, Beijnen JH, Schellens JH.Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.Oncologist 2002;7:516-30 (Pubitemid 36009000)
85. Mardones P, Andrinolo D, Csendes A, Lagos N.Permeability of human jejunal segments to gonyautoxins measured by the Ussing chamber technique.Toxicon 2004;44:521-8 (Pubitemid 39278375)
86. Yang S, Gursoy RN, Lambert G, Benita S.Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors.Pharm Res 2004;21:261-70 (Pubitemid 38221971)
87. Liu G, Franssen E, Fitch M, Warner E.Patient preference for oral versus intravenous palliative chemotherapy.J Clin Oncol 1997;24:110-15 (Pubitemid 27021524)
88. Pasquier E, Kavallaris M, Andre N.Metronomic chemotherapy: new rationale for new directions.Nat Rev Clin Oncol 2010;7:455-65
89. Weingart SN, Brown E, Bach PB, et al.NCCN task force report: oral chemotherapy.J Natl Compr Canc Netw 2008;6:S1-14
90. Terwogt JM, Schellens JH, Huinink WW, Beijnen JH.Clinical pharmacology of anticancer agents in relation to formulations and administration routes.Cancer Treat Rev 1999;25:83-101 (Pubitemid 29353668)
91. Irshad S.Considerations when choosing oral chemotherapy: identifying and responding to patient need.Eur J Cancer Care 2010;19:5-11
92. Buggins TR, Dickinson PA, Taylor G.The effects of pharmaceutical excipients on drug disposition.Adv Drug Deliv Rev 2007;59:1482-503 (Pubitemid 350122775)
93. Lo YL.Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.J Control Release 2003;90:37-48
94. Batrakova EV, Kabanov AV.Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers.J Control Release 2008;130:98-106
95. Hugger ED, Audus KL, Borchardt RT.Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers.J Pharm Sci 2002;91:1980-90 (Pubitemid 36254934)